Enjoy complimentary customisation on priority with our Enterprise License!
The heart failure drugs market share is expected to increase by USD 2.69 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 7.75%.
The heart failure drugs market has been broadly categorized into the following demographic segmentations:
This heart failure drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The heart failure drugs market report offers information on several market vendors, including Amgen Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Exelixis Inc., Gilead Sciences Inc., Novartis AG, and Pfizer Inc. among others.
Download the Free Report Sample to Unlock the Heart Failure Drugs Market Size for the Forecast Period and Other Important Statistics
The rising geriatric population is notably driving the heart failure drugs market growth, although factors such as a highly genericized market may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the heart failure drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Heart Failure Drugs Market Driver
The rising geriatric population is one of the key drivers supporting the heart failure drugs market growth. A sedentary lifestyle for several years is directly associated with the increased risk of CVDs, type 2 diabetes, and premature mortality. It has been observed in various studies that people with a sedentary lifestyle have a significantly higher rate of heart failure compared with those who lead a more active lifestyle. Moreover, there are working professionals who spend more than 50% of their day sitting without any physical movement and tend to be at a higher risk of developing CVDs such as heart failure, which will drive market growth during the forecast period.
Key Heart Failure Drugs Market Trend
Growing strategic alliances is another factor supporting the heart failure drugs market growth. As the global heart failure drugs market is highly dominated by generics, the market has the presence of many large and small players. Such fragmented nature of the market results in the distribution of profits among too many participants. As the average cost that a firm incurs toward drug development is around $2-$3 billion, such distribution provides minimal economic benefits to the market players. To overcome this situation, the market has been witnessing a growing trend of strategic alliances and acquisitions where players with strong economic positions either buy the desired drug or the entire firm. Vendors also form joint ventures for drug development or enter into a partnership, or acquire other adjacent vendors for various drugs. Such initiatives will increase the business activities of vendors, thereby driving the market growth.
Key Heart Failure Drugs Market Challenge
A highly genericized market is one of the key factors hindering the heart failure drugs market growth. The global heart failure drugs market is highly genericized, which means the generic versions of the drugs have captured a huge portion of the market. The cost-effectiveness and high affordability of these generic drugs received huge support from various government and non-government organizations, which increased the market penetration of the generic drugs further. Generic substitution (GS) successfully increased the penetration of generic drugs and reduced the overall pharmaceutical expenses of patients. However, this increased the price competition in the industry and decreased the overall revenue generated by top companies in the branded drugs market. Such factors are hindering the market growth
This heart failure drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Technavio categorizes the heart failure drugs market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the heart failure drugs market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the heart failure drugs market encompasses successful business strategies deployed by the key vendors. The heart failure drugs market is fragmented and the vendors are deploying growth strategies such as operational cost, innovation, price, and product quality to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The heart failure drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the heart failure drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
The report has further elucidated on other innovative approaches being followed by manufacturers to ensure a sustainable market presence.
***1. Executive Summary
***2. Market Landscape
**2.1 Market ecosystem
*Exhibit 01: Parent market
**2.2: Market Characteristics
*Exhibit 02: Market Characteristics
**2.2 Value chain analysis
*Exhibit 03: Value chain analysis: Pharmaceuticals
*2.2.1 Research and development (R&D) and drug discovery
*2.2.2 Integration and product development
*2.2.3 Manufacturing
*2.2.4 Outbound logistics
*2.2.5 Marketing and sales
*2.2.6 Support services
*2.2.7 Innovation
***3. Market Sizing
**3.1 Market definition
*Exhibit 04: Offerings of vendors included in the market definition
**3.2 Market segment analysis
*Exhibit 05: Market segments
**3.3 Market size 2020
**3.4 Market outlook: Forecast for 2020 - 2025
*3.4.1 Estimating growth rates for emerging and high-growth markets
*3.4.2 Estimating growth rates for mature markets
*Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
*Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)
***4. Five Forces Analysis
**4.1 Five Forces Summary
*Exhibit 08: Five forces analysis 2021 & 2026
**4.2 Bargaining power of buyers
*Exhibit 09: Bargaining power of buyers
**4.3 Bargaining power of suppliers
*Exhibit 10: Bargaining power of suppliers
**4.4 Threat of new entrants
*Exhibit 11: Threat of new entrants
**4.5 Threat of substitutes
*Exhibit 12: Threat of substitutes
**4.6 Threat of rivalry
*Exhibit 13: Threat of rivalry
**4.7 Market condition
*Exhibit 14: Market condition - Five forces 2021
***5 Market Segmentation by Drug class
**5.1 Market segments
*The segments covered in this chapter are:
*Exhibit 15: Drug class - Market share 2020-2025 (%)
**5.2 Comparison by Drug class
*Exhibit 16: Comparison by Drug class
**5.3 Beta blockers - Market size and forecast 2020-2025
*Exhibit 17: Beta blockers - Market size and forecast 2020-2025 ($ million)
*Exhibit 18: Beta blockers - Year-over-year growth 2020-2025 (%)
*Exhibit 19: Common beta blockers used for CVDs
**5.4 ARBs - Market size and forecast 2020-2025
*Exhibit 20: ARBs - Market size and forecast 2020-2025 ($ million)
*Exhibit 21: ARBs - Year-over-year growth 2020-2025 (%)
**5.5 ACE inhibitors - Market size and forecast 2020-2025
*Exhibit 22: ACE inhibitors - Market size and forecast 2020-2025 ($ million)
*Exhibit 23: ACE inhibitors - Year-over-year growth 2020-2025 (%)
**5.6 Others - Market size and forecast 2020-2025
*Exhibit 24: Others - Market size and forecast 2020-2025 ($ million)
*Exhibit 25: Others - Year-over-year growth 2020-2025 (%)
**5.7 Market opportunity by Drug class
*Exhibit 26: Market opportunity by Drug class
***6 Customer landscape
*Exhibit 27: Customer landscape
***7 Geographic Landscape
**7.1 Geographic segmentation
*Exhibit 28: Market share by geography 2020-2025 (%)
**7.2 Geographic comparison
*Exhibit 29: Geographic comparison
**7.3 North America - Market size and forecast 2020-2025
*North America - Market size and forecast 2020-2025 ($ million)
*Exhibit 31: North America - Year-over-year growth 2020-2025 (%)
**7.4 Europe - Market size and forecast 2020-2025
*Exhibit 32: Europe - Market size and forecast 2020-2025 ($ million)
*Exhibit 33: Europe - Year-over-year growth 2020-2025 (%)
**7.5 Asia - Market size and forecast 2020-2025
*Exhibit 34: Asia - Market size and forecast 2020-2025 ($ million)
*Exhibit 35: Asia - Year-over-year growth 2020-2025 (%)
**7.6 ROW - Market size and forecast 2020-2025
*Exhibit 36: ROW - Market size and forecast 2020-2025 ($ million)
*Exhibit 37: ROW - Year-over-year growth 2020-2025 (%)
**7.7 Key leading countries
*Exhibit 38: Key leading countries
**7.8 Market opportunity by geography
*Exhibit 39: Market opportunity by geography
***8 Drivers, Challenges, and Trends
**8.1 Market drivers
*8.1.1 Rising geriatric population
*8.1.2 Increase in chronic diseases
*8.1.3 Sedentary lifestyle
**8.2 Market challenges
*8.2.1 Highly genericized market
*8.2.2 Side effects of drugs
*8.2.3 Stringent regulatory guidelines
*Exhibit 40: Impact of drivers and challenges
**8.3 Market trends
*8.3.1 Growing strategic alliances
*8.3.2 Investment inclination toward developing countries
*8.3.3 New drug development
***9. Vendor Landscape
**10.1 Competitive scenario
**10.2 Vendor landscape
*Exhibit 41: Vendor Landscape
**10.3 Landscape disruption
*Exhibit 42: Landscape disruption
**10.4 Industry risks
*Exhibit 43: Industry risks
***11. Vendor Analysis
**11.1 Vendors covered
*Exhibit 44: Vendors covered
**10.2 Market positioning of vendors
*Exhibit 45: Market positioning of vendors
**10.3 Amgen Inc.
*Exhibit 46: Amgen Inc. - Overview
*Exhibit 47: Amgen Inc. - Business segments
*Exhibit 48: Amgen Inc. - Key news
*Exhibit 49: Amgen Inc. - Key offerings
**10.4 AstraZeneca Plc
*Exhibit 50: AstraZeneca Plc - Overview
*Exhibit 51: AstraZeneca Plc - Product and service
*Exhibit 52: AstraZeneca Plc - Key offerings
**10.5 Bayer AG
*Exhibit 53: Bayer AG - Overview
*Exhibit 54: Bayer AG - Business segments
*Exhibit 55: Bayer AG - Key news
*Exhibit 56: Bayer AG - Key offerings
*Exhibit 57: Bayer AG - Segment focus
** 10.6 Bristol-Myers Squibb Co
*Exhibit 58: Bristol-Myers Squibb Co. - Overview
*Exhibit 59: Bristol-Myers Squibb Co. - Product and service
*Exhibit 60: Bristol-Myers Squibb Co. - Key offerings
**10.7 Daiichi Sankyo Co. Ltd.
*Exhibit 61: Daiichi Sankyo Co. Ltd. - Overview
*Exhibit 62: Daiichi Sankyo Co. Ltd. - Business segments
*Exhibit 63: Daiichi Sankyo Co. Ltd. - Key offerings
*Exhibit 64: Daiichi Sankyo Co. Ltd. - Segment focus
**10.8 Eli Lilly and Co.
*Exhibit 65: Eli Lilly and Co. - Overview
*Exhibit 66: Eli Lilly and Co. - Business segments
*Exhibit 67: Eli Lilly and Co. - Key news
*Exhibit 68: Eli Lilly and Co. - Key offerings
**10.9 Exelixis Inc
*Exhibit 69: Exelixis Inc. - Overview
*Exhibit 70: Exelixis Inc. - Business segments
*Exhibit 71: Exelixis Inc. - Key offerings
**10.10 Gilead Sciences Inc.
*Exhibit 72: Gilead Sciences Inc. - Overview
*Exhibit 73: Gilead Sciences Inc. - Product and service
*Exhibit 74: Gilead Sciences Inc. - Key offerings
**10.11 Novartis AG
*Exhibit 75: Novartis AG - Overview
*Exhibit 76: Novartis AG - Business segments
*Exhibit 77: Novartis AG - Key news
*Exhibit 78: Novartis AG - Key offerings
*Exhibit 79: Novartis AG - Segment focus
**10.12 Pfizer Inc.
*Exhibit 80: Pfizer Inc. - Overview
*Exhibit 81: Pfizer Inc. - Business segments
*Exhibit 82: Pfizer Inc. - Key news
*Exhibit 83: Pfizer Inc. - Key offerings
***12. Appendix
**12.1 Scope of the report
*12.1.1 ????Market definition
*12.1.2 ????Objectives
*12.1.3 ????Notes and caveats
**12.2 Currency conversion rates for US$
*Exhibit 84: ?Currency conversion rates for US$?
**12.3 Research Methodology
*Exhibit 85: ?Research Methodology
*Exhibit 86: ??Validation techniques employed for market sizing?
*Exhibit 87: ??Information sources
**12.4 List of abbreviations
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.